Lv11
50 积分 2023-12-25 加入
The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma
16分钟前
已完结
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
1小时前
已完结
Targeting KRAS in cancer
1个月前
已完结
The KRAS crowd targets its next cancer mutations
1个月前
已完结
Inhibition and degradation of NRAS with a pan-NRAS monobody
1个月前
已完结
Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone
1个月前
已完结
Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone
1个月前
已完结
The mode of action of the Protein tyrosine phosphatase 1B inhibitor Ertiprotafib
2个月前
已完结
Recent updates on development of protein-tyrosine phosphatase 1B inhibitors for treatment of diabetes, obesity and related disorders
2个月前
已完结
Protein tyrosine phosphatase 1B in metabolic diseases and drug development
2个月前
已完结
皖公网安备34019202002308
